Strata Skin Sciences Q2 revenue down 9% to $7.7M; net loss widens to $2.5M, EPS -$0.60

STRATA Skin Sciences, Inc.

2025-Q2 EPS reported -$1.18 revenue$14,475,000

Revenue $7.7M (down 9% YoY); net loss $2.5M vs $0.1M loss in Q2 2024 (EPS -$0.60 vs -$0.03).
Gross profit $4.3M (56% of revenue) vs $5.0M in prior year.
Cash at June 30 $6.0M; nearly operating cash flow breakeven when adjusted for $1.3M NY tax payment and ~$340k legal costs.
CPT code expansion triples covered patient population; G-code application filed for accelerated 2026 reimbursement.
Removed 21 XTRAC devices, placed 19 (highest in six quarters); lawsuit against LaserOptek adds defendants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.